Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (7894)	7/19/2000 9:02:15 PM
From: Jim Oravetz	Respond to of 8116

July 19 /PRNewswire/ -- AxCell Biosciences Corporation, a wholly owned subsidiary of Cytogen Corporation today announced that it was invited to present at "Investing in & Commercializing New Technologies for Proteomics" on September 22, 2000 in San Francisco. The conference, which features over 30 speakers, including Wall Street analysts and bankers, venture capitalists, and representatives from academia, pharmaceutical firms and emerging proteomics companies, is sponsored by Global Business Research Ltd. "Now that the human genome has been sequenced, we are beginning to undertake the real challenge: understanding how aberrations in protein interactions within cells cause disease and how specific intervention in these pathways can treat disease," said John D. Rodwell, Ph.D., AxCell's acting President and Chief Technical Officer. "In addition to using our high- throughput methods to chart signaling pathways rapidly and identify potential drug targets, we believe that researchers will be able to use our protein arrays to test whether lead compounds cross-react with similar protein targets. Such cross-protein interactions represent the unwanted side-effects which often limit lead compound development. Overall, we believe that our customers will have a unique advantage: the combination of pathway mapping and target identification, coupled with efficient lead optimization." snip<> Jim